CAR-M + NK cells + T cells

CAR-M + NK cells + T cells refers to a combination of three distinct cell-based immunotherapies employing genetically modified immune cells—chimeric antigen receptor macrophages (CAR-M), chimeric antigen receptor natural killer cells (CAR-NK), and chimeric antigen receptor T cells (CAR-T)—designed to cooperatively target and eliminate tumor cells. Each component is an advanced cell therapy where the respective immune cell population (macrophages, NK cells, or T cells) is engineered to express chimeric antigen receptors that direct them to recognize and destroy cancer cells expressing specific antigens. CAR-T cell therapy and CAR-NK cell therapy are the most established, with multiple clinical trials and some FDA-approved treatments in hematological malignancies, and preclinical/clinical progress in solid tumors. CAR-M is a newer modality in development that uses engineered macrophages to enhance tumor phagocytosis and stimulate anti-tumor immunity. The triple combination is designed to exploit the complementary mechanisms of action of all three cell types, aiming to overcome the immune evasion and suppressive tumor microenvironment seen in cancer[1][3][4][5]. This type of multi-cellular product is investigational and remains in early/developmental phases, with no established brand names or commercial products. Indications are primarily for cancer, especially solid tumors, with ongoing research in both hematologic and solid tumors.